Clinical Significance of Computer Aided Image Analysis in Treatment Response Evaluation of Lung Cancer

Lung Cancer Clinical Trial

Official title:

Clinical Significance of Computer Aided Image Analysis in Treatment Response Evaluation of Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03954847
• Other study ID #: WuhanUH-V1.2
• Status: Recruiting
• Start date: January 1, 2012
• Est. completion date: December 31, 2020

Study information

• Verified date: May 2019
• Source: Wuhan Union Hospital, China
• Contact: Yang Jin, MD
• Phone: 027-85755457
• Email: whuhjy[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators will evaluate the utility of computer aided image analysis in lung cancer with the aim of predicting treatment response and prognosis.

Description:

Tumor biological behavior is the fundamental cause of heterogeneous prognosis. The features found on medical images are also reflections of the tumor biological behavior. However, the limitations in spatial and intensity resolution of the naked eye are two inevitable shortcomings of image interpretation by naked eyes, resulting in subjective and limited analyses of images. Computer aided image analyses such as radiomic analysis and machine learning methods are emerging as promising image interpretation methods. The natural advantage of the unlimited spatial and intensity resolution of computers can overcome the shortcomings of visual inspection with the naked eye. Moreover, the massive computing power of computer is also far greater than that of humans. This study will focus on the application of computer aided analysis in predicting treatment response and prognosis in lung cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients >= 18 years old

2. Pathological diagnosis of NSCLC between 2012 and 2019;

3. PET/CT or CT examination before any cancer-specific treatment;

Exclusion Criteria:

1. A time interval between treatment and image examination greater than 1 month;

2. A history of other malignancies

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Locations

Country	Name	City	State
China	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Wuhan Union Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	The interval between the date of diagnosis and death	2012-2021
Secondary	Progression free survival	The interval between the date of treatment initiation and disease progression	2012-2021